↓ Skip to main content

Oncogenic Viruses and Breast Cancer: Mouse Mammary Tumor Virus (MMTV), Bovine Leukemia Virus (BLV), Human Papilloma Virus (HPV), and Epstein–Barr Virus (EBV)

Overview of attention for article published in Frontiers in oncology, January 2018
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (75th percentile)
  • High Attention Score compared to outputs of the same age and source (83rd percentile)

Mentioned by

twitter
10 X users
video
1 YouTube creator

Citations

dimensions_citation
109 Dimensions

Readers on

mendeley
155 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Oncogenic Viruses and Breast Cancer: Mouse Mammary Tumor Virus (MMTV), Bovine Leukemia Virus (BLV), Human Papilloma Virus (HPV), and Epstein–Barr Virus (EBV)
Published in
Frontiers in oncology, January 2018
DOI 10.3389/fonc.2018.00001
Pubmed ID
Authors

James S. Lawson, Brian Salmons, Wendy K. Glenn

Abstract

Although the risk factors for breast cancer are well established, namely female gender, early menarche and late menopause plus the protective influence of early pregnancy, the underlying causes of breast cancer remain unknown. The development of substantial recent evidence indicates that a handful of viruses may have a role in breast cancer. These viruses are mouse mammary tumor virus (MMTV), bovine leukemia virus (BLV), human papilloma viruses (HPVs), and Epstein-Barr virus (EBV-also known as human herpes virus type 4). Each of these viruses has documented oncogenic potential. The aim of this review is to inform the scientific and general community about this recent evidence. MMTV and human breast cancer-the evidence is detailed and comprehensive but cannot be regarded as conclusive. BLV and human breast cancer-the evidence is limited. However, in view of the emerging information about BLV in human breast cancer, it is prudent to encourage the elimination of BLV in cattle, particularly in the dairy industry. HPVs and breast cancer-the evidence is substantial but not conclusive. The availability of effective preventive vaccines is a major advantage and their use should be encouraged. EBV and breast cancer-the evidence is also substantial but not conclusive. Currently, there are no practical means of either prevention or treatment. Although there is evidence of genetic predisposition, and cancer in general is a culmination of events, there is no evidence that inherited genetic traits are causal. The influence of oncogenic viruses is currently the major plausible hypothesis for a direct cause of human breast cancer.

X Demographics

X Demographics

The data shown below were collected from the profiles of 10 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 155 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 155 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 21 14%
Student > Master 19 12%
Student > Ph. D. Student 17 11%
Researcher 15 10%
Student > Doctoral Student 12 8%
Other 26 17%
Unknown 45 29%
Readers by discipline Count As %
Medicine and Dentistry 25 16%
Agricultural and Biological Sciences 20 13%
Biochemistry, Genetics and Molecular Biology 15 10%
Immunology and Microbiology 15 10%
Veterinary Science and Veterinary Medicine 7 5%
Other 18 12%
Unknown 55 35%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 August 2023.
All research outputs
#5,289,059
of 25,552,205 outputs
Outputs from Frontiers in oncology
#1,830
of 22,679 outputs
Outputs of similar age
#108,029
of 451,421 outputs
Outputs of similar age from Frontiers in oncology
#14
of 84 outputs
Altmetric has tracked 25,552,205 research outputs across all sources so far. Compared to these this one has done well and is in the 79th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 22,679 research outputs from this source. They receive a mean Attention Score of 3.0. This one has done particularly well, scoring higher than 91% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 451,421 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 75% of its contemporaries.
We're also able to compare this research output to 84 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 83% of its contemporaries.